KA
ASND icon

Kovack Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Kovack Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,430
Closed -$228K – 470
2018
Q2 		$228K Buy
3,430
+90
+3% +$5.92K 0.06% 347
2018
Q1 		$218K Buy
+3,340
New +$188K 0.05% 405

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Kovack Advisors's ASND Position: Q3 2018 in Review

Kovack Advisors sold out of Ascendis Pharma A/S (ASND) in Q3 2018, closing a stake of 3,430 shares — an estimated $228K sold.

Kovack Advisors first reported a position in ASND in Q1 2018 and held it in 2 quarters. The position peaked at $228K in Q2 2018. 96 funds tracked by Wall St. Rank hold ASND as of Q3 2018.

  • Kovack Advisors reported no remaining Ascendis Pharma A/S position as of Q3 2018 after selling out during the quarter.
  • Kovack Advisors sold 3,430 Ascendis Pharma A/S shares in Q3 2018, an estimated $228K.
  • Kovack Advisors first reported a position in Ascendis Pharma A/S in Q1 2018 and held it in 2 quarters.
  • Kovack Advisors's Ascendis Pharma A/S position peaked at $228K in Q2 2018.
  • 96 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2018.

Based on Kovack Advisors's 13F filing for Q3 2018, filed 9 Oct 2018.